Sanofi to acquire Kymab for $1.1B

By The Science Advisory Board staff writers

January 11, 2021 -- Sanofi has entered into an agreement to acquire monoclonal antibody manufacturer Kymab for an upfront payment of approximately $1.1 billion and up to $350 million in certain milestone achievements.

The transaction will give Sanofi full global rights to KY1005, a fully human monoclonal antibody that binds to the OX40 ligand and has the potential to treat a variety of immune-mediated diseases and inflammatory disorders. The candidate met primary endpoints in a phase IIB clinical trial in moderate to severe atopic dermatitis patients. KY1005 was discovered using Kymab's proprietary integrated platform, IntelliSelect, which contains a full diversity of human antibodies.

Kymab's pipeline also includes other oncology assets including KY1044, an inducible T-cell costimulator (ICOS) agonist monoclonal antibody that is in early clinical development.

Sanofi, GSK COVID-19 vaccine program delayed by responses in elderly
Sanofi and GlaxoSmithKline (GSK) are delaying their adjuvanted recombinant protein-based COVID-19 vaccine program to improve the vaccine's immune response...
Regulatory Roundup: Designations come through before year's end
This week's Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthrough, orphan, and rare disease designations...
Regulatory Roundup: Gene therapies, bispecific antibodies lead new approvals
Welcome to Regulatory Roundup, a new Science Advisory Board feature that tracks recent regulatory activities in the life sciences industry. Recent approvals...
Sanofi's continuous manufacturing facility wins award
Sanofi has won the International Society for Pharmaceutical Engineering Overall Facility of the Year Award for its digitally enabled continuous biomanufacturing...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter